Impact of melatonin on organ donor pretreatment and liver transplant recipient: prospective, randomized, double-blind trial. OBJECTIVES. To establish the efficacy of the melatonin administered to encephalic death donors (EDD) in liver transplantation. The aim is to improve the functional quality of the retrieved organs, attenuate lesions and ischemia-reperfusion mediators, and provide grafts with greater resistance to post-transplant aggression. METHODOLOGY. Prospective, randomized, double-blind, pilot trial to evaluate preconditioning with melatonin versus placebo in EDDs. Two groups, melatonin and control-placebo, n=30 per group. Administration to donor via NG tube of 30mg of melatonin or placebo (lactose) upon inclusion in the trial, 60 minutes prior to commencement of surgery and following laparotomy during extraction. Evaluation of response to treatment: A) Conventional clinical, hemodynamic, analytical and histopathological parameters in donor and recipient. B) Plasma determinations for: oxidative/nitrosative stress; acute phase proteins; cellular and humoral immunity; NT-proBNP and cystatin C; endocrine profile; melatonin levels. C) Determinations in liver tissue: quantification of malonyldialdehyde-4hydroxyalkenals and protein carbonyl content; cellular and mitochondrial membrane fluidity; markers of tissue-vascular damage and proliferation: transforming growth factor-beta (TGF-β); hypoxia-inducible factor (HIF) and vascular endothelial growth factor (VEGF). Data will be analyzed following a prospectively define plan and by intention-to-treat analysis.
This study will be done in the Hospital Clinico Lozano Blesa (Zaragoza, Spain), promoted by the Health Science Aragon Institute and its principal investigator is F. Agustín García Gil (Surgical Service). It will start in April-May 2013 and will finish 12 months later approximately. The study sponsor is I+CS (Aragon Institute of Health Sciences).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Enrollment
60
Hospital Clínico Universitario Lozano Blesa
Zaragoza, Zaragoza, Spain
AST levels
Aspartate transaminase (AST) levels will be measured.
Time frame: Between days 1 and 10 postoperatively.
ALT
Alanine transaminase (ALT) levels will be measured.
Time frame: Between days 1 and 10 postoperatively
Bilirubin levels
Bilirubin levels will be measured.
Time frame: Between days 1 and 10 postoperatively
Prothrombin levels
Prothrombin levels will be measured.
Time frame: Between days 1 and 10 postoperatively
Post-reperfusion syndrome
Post-reperfusion syndrome
Time frame: Transplant day
No primary function and primary graft dysfunction
No primary function and primary graft dysfunction
Time frame: Transplant day
Survival of the graft
Survival of the graft
Time frame: From day 0 to 3 months
Patient survival
Patient survival
Time frame: Day 0 to 3 months
Donor and recipient serological parameters
Donor and recipient serological parameters
Time frame: Between days 1 and 10 postoperatively
Morphological and functional quality of the liver graft evaluated by histological parameters of ischemia-reperfusion and tissue biochemical markers
Morphological and functional quality of the liver graft evaluated by histological parameters of ischemia-reperfusion and tissue biochemical markers
Time frame: Day 0 and day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.